Vanderbilt Institute for Therapeutic Advances

蜜桃直播

The 蜜桃直播 Institute for Therapeutic Advances represents the next frontier in translational biomedical research at Vanderbilt. One where curiosity-driven discovery is seamlessly integrated with real-world impact. VITA reinforces our commitment to supporting faculty who want to push boundaries, develop new therapies, and change the way we approach human health.

Leadership

The 蜜桃直播 Institute for Therapeutic Advances is led by scientific director , William K. Warren, Jr. Chair in Medicine and Executive Director of the .

A global leader in translational pharmacology, Lindsley holds over 130 U.S. patents and has developed more than 20 clinical candidates, including first-in-class therapeutics targeting CNS disorders. As Editor-in-Chief of Journal of Medicinal Chemistry, he continues to shape the future of drug development and innovation. Learn more about VITA leadership and the Scientific Advisory Board shaping the institute鈥檚 future.

VITA will operate at the convergence of science, data, and discovery. We鈥檝e shown what鈥檚 possible with our neuroscience pipeline. Now we鈥檙e taking that model and applying it more broadly, embedding AI, leveraging genomics, and breaking open new therapeutic areas. Our goal is clear: to generate more shots on goal, more clinical candidates, and ultimately, more cures.

Craig Lindsley
Scientific Director of the 蜜桃直播 Institute for Therapeutic Advances